Table 2.
Baseline patient demographics.
| Variable | Simple LAA morphology [n = 24] | Complex LAA morphology [n = 23] | p-value |
|---|---|---|---|
| Age, y | 65 ± 12 | 63 ± 12 | 0.60 |
| Height, cm | 167 ± 10 | 172 ± 10 | 0.59 |
| Weight, Kg | 84 ± 24 | 85 ± 24 | 0.67 |
| BMI, kg/m2 | 38 ± 54 | 29 ± 7 | 0.96 |
| CHA2DS2-VASc | 3.4 ± 1.9 | 3.2 ± 2.1 | 0.68 |
| African American, n (%) | 11 (46%) | 13 (56%) | 0.46 |
| Females, n (%) | 11 (46%) | 11 (48%) | 0.89 |
| Atrial fibrillation, n (%) | 16 (67%) | 8 (35%) | 0.03* |
| Prior stroke, n (%) | 9 (38%) | 8 (35%) | 0.85 |
| Cryptogenic stroke, n (%) | 8 (33%) | 15 (65%) | 0.03* |
| Hypertension, n (%) | 19 (79%) | 16 (70%) | 0.45 |
| Diabetes, n (%) | 8 (33%) | 10 (43%) | 0.47 |
| Hyperlipidemia, n (%) | 11 (46%) | 11 (48%) | 0.89 |
| Coronary artery disease, n (%) | 3 (12%) | 3 (13%) | 0.96 |
| Heart failure, n (%) | 6 (25%) | 4 (17%) | 0.72 |
| Coronary artery disease equivalent, n (%) | 2 (8%) | 2 (9%) | 1.00 |
| Tobacco use, n (%) | 7 (30%) | 10 (43%) | 0.36 |
| Antiplatelet therapy, n (%) | 12 (50%) | 9 (39%) | 0.45 |
| Anticoagulation therapy, n (%) | 3 (12%) | 1 (5%) | 0.61 |
| Antihypertensive therapy, n (%) | 15 (62%) | 15 (65%) | 0.85 |
| Statin therapy, n (%) | 10 (42%) | 7 (32%) | 0.85 |
| Moderate/severe mitral regurgitation, n (%) | 8 (33%) | 8 (39%) | 0.61 |
*
Significant p-value.